Tg Therapeutics, Inc.
Clinical trials sponsored by Tg Therapeutics, Inc., explained in plain language.
-
MS patients may soon get a quick shot instead of a long IV drip
Disease control OngoingThis study tests whether a shot under the skin (subcutaneous) of the drug ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 adults with MS will be randomly assigned to one of the two methods. The main goal is to compare …
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 02:47 UTC
-
MS drug ublituximab tested for Long-Term safety in 1,100 patients
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ublituximab for people with relapsing multiple sclerosis (RMS). About 1,100 participants who completed earlier studies will continue treatment. The main goal is to track how many relapses occur each year while…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC